UCB Reports Interim Results from Phase 3 BE OPTIMAL Study, Bimekizumab Met Primary and Secondary Endpoints in Patients with Active Psoriatic Arthritis

UCB Reports Interim Results from Phase 3 BE OPTIMAL Study, Bimekizumab Met Primary and Secondary Endpoints in Patients with Active Psoriatic Arthritis

UCB announced positive top-line interim analysis results from the Phase 3 BE OPTIMAL study assessing the efficacy and safety of Bimzelx (bimekizumab) in the treatment of adults with active psoriatic arthritis, who are biologic disease-modifying anti-rheumatic drug naïve. The study met the primary endpoint, and all ranked secondary endpoints with statistical significance. The study used the American College of Rheumatology (ACR) 50 response at week 16 as the primary outcome measure of improvement rather than the commonly used standard of ACR20 (i.e. 50 percent versus 20 percent improvement from baseline).  

The randomized, multicenter, double-blind, placebo-controlled, non-inferential active reference arm (adalimumab), parallel group BE OPTIMAL study was designed to evaluate the efficacy and safety of bimekizumab in the treatment of adult patients with active psoriatic arthritis, who are biologic disease-modifying anti-rheumatic drug naïve. The trial enrolled 852 participants with disease for at least six months prior to screening, and a baseline tender joint count (TJC) ≥ three out of 68 and swollen joint count (SJC) ≥ three out of 66. 

Significantly more patients treated wi...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee